KNSA: Record Q2 revenue and pipeline progress highlight strong growth and future potential
Less than 1 min read
Q2 saw record revenue growth and increased 2026 guidance, with ARCALYST showing strong market expansion and significant untapped potential. Pipeline assets KPL-387 and KPL-1161 are advancing, supported by robust clinical data and strategic focus on innovation, patient access, and long-term value.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr